Even though most people experience occasional constipation, this condition is sometimes serious and may require medical attention
Certain groups have been excluded from trials or may face additional risks, including: People who are pregnant or breastfeeding , as the safety profile in these groups has not been established Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) this exclusion reflects trial protocols and the US prescribing label for some GLP-1 receptor agonists
About the GEMINI-1 Clinical Trial The GEMINI-1 clinical trial was a multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical study (NCT06396429) conducted by Hengrui in China to evaluate the efficacy and safety of HRS9531 injection in adults (18 years of age) with obesity (BMI 28 kg/m 2 ) or overweight (BMI 24 kg/m 2 ) and at least one weight-related comorbidity without diabetes
This option is best suited for those who are comfortable working with typical research-grade variability
Routine monitoring of electrolytes, including potassium, is not universally required for all patients on semaglutide, but certain clinical scenarios warrant closer surveillance as outlined in NICE guidance (NG28)
Gawdiya S, Kumar D, Shivay YS, Kour B, Kumar R, Meena S, Saini R, Choudhary K, Al-Ansari N, Alataway A, Dewidar AZ, Mattar MA
